These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18615074)

  • 1. Cancer: An unexpected addiction.
    Shaughnessy JD
    Nature; 2008 Jul; 454(7201):172-3. PubMed ID: 18615074
    [No Abstract]   [Full Text] [Related]  

  • 2. IRF4 addiction in multiple myeloma.
    Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
    Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
    Weinhold N; Meissner T; Johnson DC; Seckinger A; Moreaux J; Försti A; Chen B; Nickel J; Chubb D; Rawstron AC; Doughty C; Dahir NB; Begum DB; Young K; Walker BA; Hoffmann P; Nöthen MM; Davies FE; Klein B; Goldschmidt H; Morgan GJ; Houlston RS; Hose D; Hemminki K
    Haematologica; 2015 Mar; 100(3):e110-3. PubMed ID: 25480495
    [No Abstract]   [Full Text] [Related]  

  • 4. Aberrant translational control of the c-myc gene in multiple myeloma.
    Paulin FE; West MJ; Sullivan NF; Whitney RL; Lyne L; Willis AE
    Oncogene; 1996 Aug; 13(3):505-13. PubMed ID: 8760292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adhesive interactions regulate transcriptional diversity in malignant B cells.
    Nadav-Dagan L; Shay T; Dezorella N; Naparstek E; Domany E; Katz BZ; Geiger B
    Mol Cancer Res; 2010 Apr; 8(4):482-93. PubMed ID: 20371671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
    Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
    Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional regulation and transformation by Myc proteins.
    Adhikary S; Eilers M
    Nat Rev Mol Cell Biol; 2005 Aug; 6(8):635-45. PubMed ID: 16064138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene addiction: sometimes a temporary slavery.
    Jonkers J; Berns A
    Cancer Cell; 2004 Dec; 6(6):535-8. PubMed ID: 15607957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of c-myc-mRNA and c-MYC-protein during terminal neoplastic B-cell differentiation.
    Greil R; Loidl P; Fasching B; Huber H
    Curr Top Microbiol Immunol; 1992; 182():215-21. PubMed ID: 1490357
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of primary MAFB target genes in multiple myeloma.
    van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
    Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.
    Pattengale PK
    Am J Pathol; 1997 Sep; 151(3):647-9. PubMed ID: 9284811
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomic profiling of enzastaurin-treated B cell lymphoma RL cells.
    Civallero M; Cosenza M; Neri A; Bari A
    Hematol Oncol; 2011 Sep; 29(3):154-6. PubMed ID: 21922509
    [No Abstract]   [Full Text] [Related]  

  • 13. Over-expression of c-myc oncoprotein in B lymphocytes of renal transplant recipients with lymphoproliferative disorders.
    Sabido O; Alamartine E; Barthelemy JC; Berthoux F
    Transplantation; 1993 Aug; 56(2):467-70. PubMed ID: 8395101
    [No Abstract]   [Full Text] [Related]  

  • 14. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
    Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
    Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo study on the effects of microcystin extracts on the expression profiles of proto-oncogenes (c-fos, c-jun and c-myc) in liver, kidney and testis of male Wistar rats injected i.v. with toxins.
    Li H; Xie P; Li G; Hao L; Xiong Q
    Toxicon; 2009 Jan; 53(1):169-75. PubMed ID: 19041662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages and abnormal BCL-6 or c-MYC gene expression affect the resistance of peritoneal B cells to induction of hyporesponsiveness.
    Liou LB; Wu MW; Chao WJ
    Scand J Immunol; 2009 May; 69(5):447-56. PubMed ID: 19508376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene regulation: fine-tuned amplification in cells.
    Dang CV
    Nature; 2014 Jul; 511(7510):417-8. PubMed ID: 25043013
    [No Abstract]   [Full Text] [Related]  

  • 18. Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements.
    Högstrand K; Lindvall JM; Sundblad A; Grandien A
    Eur J Immunol; 2019 Mar; 49(3):454-461. PubMed ID: 30664244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct regulation of HSP60 expression by c-MYC induces transformation.
    Tsai YP; Teng SC; Wu KJ
    FEBS Lett; 2008 Dec; 582(29):4083-8. PubMed ID: 19022255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
    Li N; Johnson DC; Weinhold N; Studd JB; Orlando G; Mirabella F; Mitchell JS; Meissner T; Kaiser M; Goldschmidt H; Hemminki K; Morgan GJ; Houlston RS
    Nat Commun; 2016 Nov; 7():13656. PubMed ID: 27882933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.